Chardan Capital Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $218.00

Krystal Biotech (NASDAQ:KRYS) had its price target boosted by Chardan Capital from $212.00 to $218.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on KRYS. Citigroup upped their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Trading Up 3.7 %

NASDAQ:KRYS opened at $182.62 on Thursday. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The firm has a market capitalization of $5.25 billion, a price-to-earnings ratio of 61.08 and a beta of 0.84. The firm’s fifty day simple moving average is $157.18 and its 200 day simple moving average is $175.18.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same quarter in the previous year, the firm posted $0.30 earnings per share. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. On average, analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently modified their holdings of the stock. Summit Trail Advisors LLC bought a new stake in Krystal Biotech in the third quarter valued at about $1,893,000. Entropy Technologies LP acquired a new position in shares of Krystal Biotech in the 4th quarter worth approximately $548,000. Swiss National Bank increased its holdings in shares of Krystal Biotech by 8.0% in the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after acquiring an additional 2,900 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after acquiring an additional 15,545 shares in the last quarter. Finally, Citigroup Inc. raised its position in shares of Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).